FDA Drug recall D-1271-2019
BEVACIZUMAB 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection
- FDA Drug
- Class II
- terminated
- Published 2019-05-08
On 2019-05-08 the FDA classified a Class II recall of BEVACIZUMAB 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection by Pacifico National, citing defective Delivery System: difficult to express.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1271-2019 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2019-04-19 |
| Published | 2019-05-08 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Pacifico National |
| Distribution | US |
Product
BEVACIZUMAB 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection. This biologic product was repackaged by AmEx Pharmacy 1515 Elizabeth St. Suite J Melbourne, FL 32901 Lot:190212AB BUD:5/13/2019, Repackaged on 2/12/2019
Reason
Defective Delivery System: difficult to express
Identifiers
| code_info | Lot: 190212AB BUD: 5/13/2019 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1271-2019%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.